Matsuura J E, Swaney J B
Department of Biological Chemistry, Hahnemann University, Philadelphia, PA 19102.
J Lipid Res. 1991 Apr;32(4):581-94.
It is known that an acute hepatotoxicity is produced in rats by intraperitoneal administration of galactosamine; a consequence of this treatment is a marked deficiency of lecithin:cholesterol acyltransferase (LCAT) activity in the plasma compartment. In this study high density lipoprotein (HDL) from galactosamine-treated rats was isolated, resolved into subpopulations, and characterized. In contrast to HDL from control rats, which elutes from gel filtration columns as a single peak and has a diameter of 13.1 nm, HDL from the galactosamine-treated animals was found to elute in five major zones with diameters of 7.8-35 nm. Characterization of these subpopulations has revealed that the larger fractions are enriched in apolipoprotein E, phospholipid, and cholesterol, but contain little cholesteryl ester, while the smallest two fractions contain mainly apolipoprotein A-I, are enriched in phospholipid, and have 50-60% of their cholesterol in the ester form. Incubation of HDL from treated rats with a source of LCAT activity plus low and very low density lipoproteins caused transformation of these subpopulations into a species which, by size and composition, was essentially identical to control rat HDL. In addition, when the subpopulations were individually incubated with purified human lecithin:cholesterol acyltransferase and bovine serum albumin, there was a similar convergence toward a moderate particle size approximating control rat HDL. Cross-linking studies showed that incubation with LCAT activity reduced the heterogeneity of the treated rat HDL. We conclude that the galactosamine treatment induces a complex mixture of HDL that bears strong similarities to the small, apoA-I rich and large, apoE-rich particles seen in LCAT deficiency or secreted by hepatic cells in culture. Furthermore, these species appear to coalesce in the presence of the d greater than 1.21 g/ml fraction of control serum to yield a fairly homogeneous population that resembles control rat HDL in size, composition, and apoprotein content.
已知腹腔注射半乳糖胺可在大鼠中产生急性肝毒性;这种处理的一个后果是血浆中卵磷脂:胆固醇酰基转移酶(LCAT)活性显著缺乏。在本研究中,分离了半乳糖胺处理大鼠的高密度脂蛋白(HDL),将其解析为亚群并进行表征。与对照大鼠的HDL不同,对照大鼠的HDL从凝胶过滤柱上以单峰形式洗脱,直径为13.1nm,而半乳糖胺处理动物的HDL在五个主要区域洗脱,直径为7.8 - 35nm。对这些亚群的表征表明,较大的部分富含载脂蛋白E、磷脂和胆固醇,但胆固醇酯含量很少,而最小的两个部分主要含有载脂蛋白A - I,富含磷脂,其胆固醇的50 - 60%以酯的形式存在。将处理大鼠的HDL与LCAT活性来源以及低密度和极低密度脂蛋白一起孵育,导致这些亚群转变为一种在大小和组成上与对照大鼠HDL基本相同的物质。此外,当将这些亚群分别与纯化的人卵磷脂:胆固醇酰基转移酶和牛血清白蛋白孵育时,也会朝着接近对照大鼠HDL的中等粒径发生类似的趋同。交联研究表明,与LCAT活性孵育可降低处理大鼠HDL的异质性。我们得出结论,半乳糖胺处理诱导了一种复杂的HDL混合物,其与LCAT缺乏症中所见的富含载脂蛋白A - I的小颗粒和富含载脂蛋白E的大颗粒或培养肝细胞分泌的颗粒有很强的相似性。此外,在对照血清中密度大于1.21g/ml的部分存在时,这些物质似乎会合并,产生一个在大小、组成和载脂蛋白含量上类似于对照大鼠HDL的相当均匀的群体。